Abbott India Ltd.
ABBOTINDIANSEHealthcarePharmaceuticals & DrugsMid Cap
₹26,225
▲ 0.61%
—
Composite
The company is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
Q-DITS fundamental score
—Composite
Growth
50
Profitability
95
Valuation
0
Quality
97
Solvency
100
Earnings
54
Key metrics
MCap
₹55.8K Cr
TTM PE
46.2x
Industry PE
37.7x
TTM EPS
—
Book Value
—
Face Value
₹10
Div Yield
2.5%
PEG
—
PB
15.5x
ROE
36%
ROCE
47.9%
EBITDA mgn
29.9%
D/E
0
Int. Cover
166.1x
Curr. Ratio
3.37x
EPS
₹665.62
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 8.1% | 9% | 10% | 10.1% |
| EBITDA | 11.7% | 16.2% | 15.5% | 17.9% |
| Net Profit | 9.7% | 17.8% | 17.6% | 19.8% |
Score snapshot
Piotroski
6/9
Altman Z
3.06
Quality
97.1
Growth
49.5
Valuation
—
Earn. Qual
54.4
PEAD
0
SURGE
0
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 10 years
Tap any row to see its trend
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 2,615 | 2,903 | 3,299 | 3,679 | 4,093 | 4,310 | 4,913 | 5,349 | 5,849 | 6,409 | ↑ |
| ›EBITDACr | 415 | 455 | 641 | 718 | 871 | 1,002 | 1,165 | 1,360 | 1,701 | 1,970 | ↑ |
| ›EBITDA margin | 15.7% | 15.5% | 19.4% | 19.5% | 21.3% | 22.4% | 23.2% | 24.8% | 28.2% | 29.9% | ↑ |
| ›Net profitCr | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | ↑ |
| ›PAT margin | 9.6% | 9.4% | 12.1% | 12.2% | 14.5% | 15.5% | 15.9% | 17.3% | 19.9% | 21.4% | ↑ |
| ›EPS₹ | ₹120.12 | ₹130.19 | ₹188.81 | ₹211.93 | ₹279.03 | ₹325.03 | ₹375.86 | ₹446.78 | ₹565.28 | ₹665.62 | ↑ |
| ›Revenue growth | 14.2% | 11% | 13.6% | 11.5% | 11.3% | 5.3% | 14% | 8.9% | 9.4% | 9.6% | ↑ |
| ›PAT growth | 11.5% | 8.4% | 45% | 12.2% | 31.7% | 16.5% | 15.6% | 18.9% | 26.5% | 17.8% | ↓ |
| ›ROE | 23.9% | 21.5% | 26.3% | 24.7% | 27.1% | 27.9% | 30% | 32.1% | 35.3% | 36% | ↑ |
| ›ROCE | 37.6% | 34% | 40.6% | 37.9% | 36.5% | 37.5% | 40.5% | 42.9% | 47.3% | 47.9% | ↑ |
| ›ROA | 13.4% | 15.1% | 18% | 16.9% | 18.4% | 18.8% | 19.9% | 21.7% | 24.7% | 25.5% | ↑ |
| ›P/E | 39.2x | 35.6x | 28.9x | 34.4x | 55.4x | 46.1x | 47.1x | 49.4x | 47.7x | 46.2x | ↓ |
| ›P/B | 8.4x | 7.2x | 6.9x | 7.8x | 13.7x | 12.5x | 13.6x | 14.9x | 15.7x | 15.5x | ↓ |
| ›D/E | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| ›Current ratio | 3.8x | 3x | 3.3x | 3.2x | 3.6x | 3.4x | 3.2x | 2.5x | 2.4x | 3.4x | ↑ |
| ›Interest cover | 158.6x | 215.3x | 163.6x | 311.8x | 95.1x | 51.7x | 57.5x | 80.7x | 130.9x | 166.1x | ↑ |
Quarterly results
Tap any row to see its trend
| Metric | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | ↓ |
| ›Rev growth YoY | 8.7% | 7.1% | 5.3% | 9.3% | 12.3% | 11.5% | 11.6% | 7.6% | 6.8% | 6.5% | ↓ |
| ›EBITDACr | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | ↑ |
| ›EBITDA margin | 27% | 22.9% | 25.1% | 26.9% | 27% | 26.7% | 25.6% | 28.6% | 26.9% | 28.1% | ↑ |
| ›Net profitCr | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | ↑ |
| ›PAT growth YoY | 26% | 24% | 13% | 14.6% | 16% | 27.9% | 11.5% | 15.8% | 4.2% | 7.6% | ↑ |
| ›EPS₹ | ₹146.34 | ₹135.09 | ₹154.36 | ₹168.76 | ₹169.78 | ₹172.72 | ₹172.17 | ₹195.42 | ₹176.92 | ₹185.85 | ↑ |
Balance sheet — last 10 years (₹ Cr)
Tap any row to see its trend
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 1,387 | 1,693 | 2,009 | 2,432 | 2,602 | 2,820 | 3,189 | 3,699 | 4,233 | 4,774 | ↑ |
| ›ReservesCr | 1,352 | 1,651 | 1,960 | 2,375 | 2,537 | 2,754 | 3,125 | 3,637 | 4,183 | 4,753 | ↑ |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| ›InvestmentsCr | 45 | 53 | 61 | 56 | 84 | 82 | 1,273 | 1,697 | 783 | 0 | ↓ |
| ›Total assetsCr | 1,434 | 1,748 | 2,084 | 2,656 | 2,810 | 3,021 | 3,349 | 3,851 | 4,510 | 6,502 | ↑ |
| ›Current assetsCr | 1,893 | 2,231 | 2,761 | 3,205 | 3,487 | 3,853 | 3,025 | 3,246 | 4,742 | 3,640 | ↓ |
| ›Current liabilitiesCr | 632 | 668 | 857 | 891 | 1,031 | 1,203 | 1,206 | 1,343 | 1,407 | 1,438 | ↑ |
| ›Trade payablesCr | 475 | 481 | 664 | 658 | 763 | 889 | 892 | 1,003 | 1,058 | 1,107 | ↑ |
| ›Gross blockCr | 140 | 124 | 165 | 345 | 341 | 426 | 367 | 425 | 596 | 162 | ↓ |
Cash flow statement (₹ Cr)
Tap any row to see its trend
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 | 1,319 | ↑ |
| ›Investing CF (CFI)Cr | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 | -371 | ↓ |
| ›Financing CF (CFF)Cr | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 | -1,066 | ↓ |
| ›Net cash changeCr | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 | -118 | ↓ |
| ›Closing cashCr | 202 | 38 | 137 | 145 | 218 | 133 | 240 | 292 | 561 | 442 | ↓ |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
—
Quality (25%)97.1
Growth (25%)49.5
Valuation (20%)—
Piotroski (15%)67
Earnings Quality (10%)54.4
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
6/9
✓ROA positiveROA 25.53%
✓CFO positiveCFO ₹1319.24 Cr
✓ROA improving24.73% → 25.53%
✗CFO > PAT (low accruals)CFO 1319.24 vs PAT 1414.44
✗Leverage decreasedD/E 0.0 → 0.0
✓Liquidity improvedCR 2.42 → 3.37
✓No share dilutionEPS 565.28 → 665.62
✓Margin improvedEBITDA mgn 28.15% → 29.85%
✗Asset turnover upAsset TO 1.24 → 1.19
Altman Z-Scoresafe
3.06
X1
0.339
X2
0.731
X3
0.292
X4
0.734
X5
0.986
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
97.1/100
ROE
36%
ROCE
47.9%
Margin
21.4%
Debt
0
Int. cover
166.1x
Growth
49.5/100
Revenue 3Y
9%
Profit 3Y
17.8%
EPS
17.8%
Valuation
N/A
PE
—
PB
—
EV/EBITDA
—
Earnings quality
54.4/100
CFO₹1,319 Cr
PAT₹1,414 Cr
Accrual ratio0.015
CFO/PAT0.93x
PEAD · SURGE
0 / 0
Revenue SUE-1.03
EPS SUE1.19
Latest quarter2026-03
Rev growth YoY6.5%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,30,513 | 58,462 | 11,565 | 37.5x | 5.2x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,76,570 | 10,560 | 2,568 | 68.8x | 10.5x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,54,670 | 13,980 | 2,138 | 71.5x | 18.4x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,11,725 | 28,163 | 3,870 | 28.8x | 3.3x | 11.8 | 16 | 0.01 |
| Zydus Lifesciences Ltd. | 1,11,254 | 27,148 | 5,026 | 22.1x | 4.1x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,424 | 33,700 | 4,144 | 25.4x | 2.8x | 18.6 | 23.3 | 0.14 |
| Lupin Ltd. | 1,03,975 | 27,958 | 5,355 | 19.5x | 4.6x | 21.1 | 22 | 0.3 |